227 related articles for article (PubMed ID: 19937695)
1. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.
Lange CM; Bojunga J; Hofmann WP; Wunder K; Mihm U; Zeuzem S; Sarrazin C
Hepatology; 2009 Dec; 50(6):2001-6. PubMed ID: 19937695
[TBL] [Abstract][Full Text] [Related]
2. Short-term entecavir therapy of chronic severe hepatitis B.
Chen J; Han JH; Liu C; Yu RH; Li FZ; Li QF; Gong GZ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):261-6. PubMed ID: 19502165
[TBL] [Abstract][Full Text] [Related]
3. Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis.
Marzano A; Marengo A; Marietti M; Rizzetto M
Dig Liver Dis; 2011 Dec; 43(12):1027-8. PubMed ID: 21782535
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
6. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
9. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B.
McKenzie R; Fried MW; Sallie R; Conjeevaram H; Di Bisceglie AM; Park Y; Savarese B; Kleiner D; Tsokos M; Luciano C
N Engl J Med; 1995 Oct; 333(17):1099-105. PubMed ID: 7565947
[TBL] [Abstract][Full Text] [Related]
10. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
[TBL] [Abstract][Full Text] [Related]
11. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
12. [Case-controlled study of entecavir treatment for chronic severe hepatitis B].
Xiao GM; He KY; Jia WD; Lei CL; Yang Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Feb; 23(1):56-8. PubMed ID: 19799020
[TBL] [Abstract][Full Text] [Related]
13. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Chang TT; Chao YC; Gorbakov VV; Han KH; Gish RG; de Man R; Cheinquer H; Bessone F; Brett-Smith H; Tamez R
J Viral Hepat; 2009 Nov; 16(11):784-9. PubMed ID: 19457141
[TBL] [Abstract][Full Text] [Related]
14. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
15. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
16. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Sims KA; Woodland AM
Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
[TBL] [Abstract][Full Text] [Related]
17. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
19. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
[TBL] [Abstract][Full Text] [Related]
20. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
